Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4